Stocks:
5,167
ETFs:
2,288
Exchanges:
11
Market Cap:
$62.23T
24h Vol:
$9.02B
Dominance:
MSFT:4.87%
Stocklytics Platform
Instrument logo  ABEO
Abeona Therapeutics
ABEO
72 / 100
Penny Stock
$3.18arrow_drop_down6.59%-$0.22

Performance History

Stocklytics logo
Key Stats
Open$3.45
Prev. Close$3.41
EPS-2.53
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap207350896.00
PE Ratio-
LOWHIGH
Day Range3.14
3.52
52 Week Range2.83
9.01
Ratios
P/B Ratio13.93
Revenue$3.50M
Operating M. %-1,377.14%
Earnings$0.00
Earnings Growth %-36.51%
EBITDA Margin %-1,000.00%
ROE %-260.60%
EPS-2.53

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

72vs 56. Market Avg.

All Score 72 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

ABEOMARKET
Value6940
Quality5540
Ownership2717
Growth6045
Dividends-38
check_circle

Abeona Therapeutics 's Price discount from all time high of 100% is great compared to market average of 42.03%. This indicates ABEO could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$732.20
24H (%)arrow_drop_down1.80%
24H ($)-$13.48
MARKET CAP$695.32B
PRICE$487.29
24H (%)arrow_drop_up0.23%
24H ($)$1.12
MARKET CAP$452.88B
PRICE$148.53
24H (%)arrow_drop_down0.68%
24H ($)-$1.03
MARKET CAP$359.34B
PRICE$127.00
24H (%)arrow_drop_up0.09%
24H ($)$0.12
MARKET CAP$321.39B

About Abeona Therapeutics (ABEO)

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Vishwas Seshadri M.B.A., Ph.D.
Headquarters
New York
Employees
57
Exchange
NASDAQ
add Abeona Therapeutics  to watchlist

Keep an eye on Abeona Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Abeona Therapeutics 's (ABEO) price per share?

The current price per share for Abeona Therapeutics (ABEO) is $3.17. The stock has seen a price change of -$0.24 recently, indicating a -7.04% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Abeona Therapeutics (ABEO)?

For Abeona Therapeutics (ABEO), the 52-week high is $9.01, which is 184.23% from the current price. The 52-week low is $2.83, the current price is 12.01% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Abeona Therapeutics (ABEO) a growth stock?

Abeona Therapeutics (ABEO) has shown an average price growth of -42.96% over the past three years. It has received a score of 10 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Abeona Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Abeona Therapeutics (ABEO) stock price performance year to date (YTD)?

As of the latest data, Abeona Therapeutics (ABEO) has a year-to-date price change of -42.47%. Over the past month, the stock has experienced a price change of -57.34%. Over the last three months, the change has been -33.12%. Over the past six months, the figure is -21.53%. Looking at a longer horizon, the five-year price change stands at -98.47%.

help
Is Abeona Therapeutics (ABEO) a profitable company?

Abeona Therapeutics (ABEO) has a net income of -$54.19M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 8.63% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.38K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $3.5M, although specific revenue growth data is currently not available. The gross profit is $302K. Operating income is noted at -$48.2M. Furthermore, the EBITDA is -$45.91M.

help
What is the market capitalization of Abeona Therapeutics (ABEO)?

Abeona Therapeutics (ABEO) has a market capitalization of $207.35M. The average daily trading volume is 1.08M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.